WO1993016717A1 - Method and agents for promoting wound healing - Google Patents
Method and agents for promoting wound healing Download PDFInfo
- Publication number
- WO1993016717A1 WO1993016717A1 PCT/US1993/001677 US9301677W WO9316717A1 WO 1993016717 A1 WO1993016717 A1 WO 1993016717A1 US 9301677 W US9301677 W US 9301677W WO 9316717 A1 WO9316717 A1 WO 9316717A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- group
- mixtures
- wound healing
- advanced glycosylation
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title claims abstract description 100
- 238000000034 method Methods 0.000 title claims description 59
- 230000001737 promoting effect Effects 0.000 title claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 119
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 239000000463 material Substances 0.000 claims abstract description 36
- 229920001436 collagen Polymers 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 102000008186 Collagen Human genes 0.000 claims abstract description 23
- 108010035532 Collagen Proteins 0.000 claims abstract description 23
- 230000027455 binding Effects 0.000 claims abstract description 22
- 108090001008 Avidin Proteins 0.000 claims abstract description 17
- 235000000346 sugar Nutrition 0.000 claims abstract description 15
- 108010088751 Albumins Proteins 0.000 claims abstract description 14
- 102000009027 Albumins Human genes 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims abstract description 12
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 12
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108010083644 Ribonucleases Proteins 0.000 claims abstract description 11
- 102000006382 Ribonucleases Human genes 0.000 claims abstract description 11
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 11
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 claims abstract description 9
- 229930091371 Fructose Natural products 0.000 claims abstract description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 9
- 239000005715 Fructose Substances 0.000 claims abstract description 9
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 claims abstract description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 9
- 230000004064 dysfunction Effects 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 230000003779 hair growth Effects 0.000 claims abstract description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 63
- 206010052428 Wound Diseases 0.000 claims description 60
- 230000000694 effects Effects 0.000 claims description 36
- 108010053481 Antifreeze Proteins Proteins 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 239000007943 implant Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 241000894007 species Species 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 150000001720 carbohydrates Chemical group 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 239000000025 natural resin Substances 0.000 claims description 6
- 239000000057 synthetic resin Substances 0.000 claims description 6
- 229920003002 synthetic resin Polymers 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 238000010348 incorporation Methods 0.000 claims description 3
- 229940045189 glucose-6-phosphate Drugs 0.000 claims 6
- 230000002708 enhancing effect Effects 0.000 claims 4
- 239000003356 suture material Substances 0.000 claims 3
- 239000000560 biocompatible material Substances 0.000 claims 2
- 238000005516 engineering process Methods 0.000 claims 2
- 230000002068 genetic effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000008427 tissue turnover Effects 0.000 abstract description 2
- 239000003357 wound healing promoting agent Substances 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 17
- 230000035876 healing Effects 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 208000005775 Parakeratosis Diseases 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 108010050619 Monokines Proteins 0.000 description 2
- 102000013967 Monokines Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 235000000126 Styrax benzoin Nutrition 0.000 description 2
- 244000028419 Styrax benzoin Species 0.000 description 2
- 235000008411 Sumatra benzointree Nutrition 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960002130 benzoin Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- -1 glucose Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000019382 gum benzoic Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 108091005446 macrophage receptors Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 101710104316 Cell surface-binding protein Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 108010055267 advanced glycation end products-bovine serum albumin Proteins 0.000 description 1
- 108010066167 advanced glycation end products-human serum albumin Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 description 1
- 229950003616 azaperone Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 229940080861 demerol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- DKZNJXJLTVYBRA-UHFFFAOYSA-N furan-2-yl-[5-(furan-2-yl)-1h-imidazol-2-yl]methanone Chemical compound C=1C=COC=1C(=O)C(N1)=NC=C1C1=CC=CO1 DKZNJXJLTVYBRA-UHFFFAOYSA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Definitions
- the present invention generally relates to the repair of damaged tissues in animals and particularly humans, and, more particularly, to the modulation of the healing of wounds in such tissue.
- tissue wounds occurs from an endless variety • of pathological and non-pathological causes.
- a variety of cells have been determined to cooperate to repair the damaged tissue and heal the wound.
- Cells resident in the local tissue participate, as do circulating blood cells specifically recruited into the wound itself and the area nearby.
- Dramatic changes in cellular function are required by both the resident and recruited cells in order to initiate, coordinate, and sustain the complex process of wound healing. Damaged cells and disrupted tissue matrix must be removed, new cells must be formed, and must grow and mature to replace those lost.
- the tissue matrix must be resynthesized and remodeled, and even the microvasculature may need to be rebuilt to supply the new tissue.
- AGEs advanced glycosylation endproducts
- reducing sugars e.g., glucose
- protein amino groups react non-enzymatically with protein amino groups to form a diverse series of protein bound moieties with fluorescent and crosslinking properties.
- These compounds have been implicated in structural and functional alteration of proteins during aging and in certain diseases that are considered degradative and undesirable, e.g., the embrittlement of structural proteins observed in long-term diabetes.
- AGEs have been identified on the basis of de novo synthesis and tissue isolation procedures.
- diagnostic and therapeutic protocols are proposed that are predicated in part on the discovery that advanced glycosylation endproducts (AGEs) and other agents previously described for the promotion of the vivo recognition and removal of AGEs, possess a definitive modulating effect upon the progression of tissue reconstruction and wound healing in mammals, and are capable of stimulating and promoting both activities.
- AGEs advanced glycosylation endproducts
- the present invention relates in its broadest aspect to the treatment of wounds as well as various wound healing dysfunctions by the administration of a wound healing modulator comprising a material selected from the group consisting of agents capable of modulating wound healing, binding partners thereto, and the muteins and fragments thereof, wherein the agents are selected from advanced glycosylation endproducts (AGEs), compositions and complexes containing advanced glycosylation endproducts alone or bound to a carrier, derivatives thereof, and mixtures thereof.
- the carrier may include a material selected from carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
- the agent could include other advanced glycosylation endproducts that may be prepared synthetically or from the reaction between sugars and other macromolecules, and monokines which stimulate phagocytic cells to increase their activity toward advanced glycosylation endproducts.
- the agent may comprise the compounds FFI or AFGP bound to a protein such as albumin.
- the agent may comprise a synthetically derived advanced glycosylation endproduct which is prepared, for example, by the reaction of glucose or glucose-6-phosphate with albumin. This reaction product can be used alone or with a carrier in the same fashion as the FF1- albumin complex.
- a monokine that functions as an agent comprises the protein known as Tumor Necrosis Factor (TNF) and its variant discovered and isolated by one of the inventors herein and named "cachectin". This material may be administered alone or in conjunction with other agents.
- TNF Tumor Necrosis Factor
- the agents of the present invention may be administered in conjunction with materials identified hereinafter as "co-stimulatory" agents.
- co-stimulatory agents include monokines such as lnterleukin-1 (IL-1 ) and gamma-interferon.
- AGEs useful in accordance herewith may be introduced to particular tissues by injection to stimulate and promote cellular growth or regrowth, in some instances, that will result in the structural and functional enhancement of the treated tissues.
- the growth stimulating effect of the modulators of the invention finds a further application in the promotion of tissue acceptance and the corresponding limitation or inhibition of tissue rejection in tissue transplantation and reconstruction.
- fibers implanted to promote tissue regrowth, transplanted organs or synthetic organs prepared in some instances, at least in part from structural proteinaceous material such as collagen may have applied to them one or more of the present wound healing modulators before implantation, to promote acceptance of the exogenous material and incorporation into the target tissue.
- the modulators in this instance may be bound to the protein or may be otherwise adherently applied as a coating by known techniques. Accordingly, the invention extends to the corresponding prosthetic materials having the modulators applied as a coating thereto, or chemically linked by known methods such as for example, coupling thereto a synthetic AGE such as FFI-BSA or the like.
- modulators of the present invention derives from the observations presented below, that the application of the wound healing modulator to skin stimulates hair growth. It is apparent from this that the stimulation of hair growth may be achieved by the topical or intradermal application of the present modulators, and the present invention accordingly extends to a method of stimulating hair growth thereby.
- This method may comprise the local application of the modulator to the dermal area, with the formulation of the modulator dosage contemplating both topical applications and if appropriate, dermal implants or injections.
- the AGEs that may serve as agents may comprise the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose and ribose; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
- the agent may comprise an advanced glycosylation endproduct selected from the group consisting of the chromophores 2-(2-furoyl)-4(5)-(2-furanyl)-1 H_-imidazole (FFI), 1 -alkyl-2-formyl-3,4-diglycosyl-pyrrole (AFGP), alone and coupled to carriers such as BSA, HSA, and avidin.
- Suitable agents also include materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity, such as homologous agents derived synthetically or from other cellular sources or from other species.
- the agent binding partners contemplated by the invention include anti-agent antibodies, receptors for the agents, materials not antibodies that antagonize the production and/or wound healing modulating activity of the agents, binding partners thereto, and other binding partners thereof.
- the present wound healing modulators may comprise materials that are capable of acting in vivo, and in a further embodiment, may be promoters of wound healing.
- the invention accordingly includes a method for promoting wound healing comprising administering an effective amount of one of the above wound healing modulators individually, or in mixture with each other or formulated as a pharmaceutical composition.
- the modulators contemplated for use in this method comprise those agents and binding partners that act as promoters of wound healing, and extend for example, to homologous agents derived from other cellular sources or from other species, materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity.
- compositions may be prepared in accordance with the invention and comprise therapeutically effective amounts of the present wound healing modulators, either alone or in admixture with each other, and a pharmaceutically acceptable diluent or carrier.
- the modulators may preferably be present in amounts effective to deliver at least 100 ng/cm 2 and preferably from about 1 ⁇ gfcm 2 to about 10 g/cm 2 thereof.
- the therapeutic methods of the present invention apply generally to mammals and contemplate veterinary use as well as application to humans.
- the particular therapeutic protocols will vary accordingly upon the subject of treatment.
- the present invention contemplates a method for measuring the activity of the wound healing modulators of the present invention.
- the method comprises retrieving a sample of wound fluid which such disorder is suspected, and incubating the sample with a quantity of a wound healing modulator of the present invention bearing an appropriate detectable label.
- the sample may thereafter be examined to determine whether such aberrant cellular activity is due to a deficiency in wound healing factor presence or activity, and to thereby attempt to isolate and identify the cause of such disorder.
- the present invention may also extend to appropriate new drug assays and test kits including the wound healing modulators of the present invention. Accordingly, it is a principal object of the present invention to provide a method for treating wound healing dysfunctions in mammals.
- compositions for use in therapeutic methods for treating wound healing dysfunctions and/or promoting wound healing which comprise or are based upon certain wound healing modulators including agents and their binding partner(s).
- wound healing modulator refers to protein material having the profile of activities set forth herein and in the Claims.
- AGE and “AGEs” are used as appropriate to refer to advanced glycosylation endproducts which are in the form of stable compounds and intermediates which are produced synthetically, ]n vivo, and ]n vitro by the reaction of reducing sugars with protein amino groups. AGEs therefore encompass intermediates as well as stable endproducts that are implicated in the structural and functional alteration of proteins seen during aging. For example, AGEs are recognized to react with free polypeptide amino groups, which leads to protein crosslinking. Additionally, such AGES are observed in elevated levels in circulation and in tissues in certain diseases, e.g. diabetes mellitus.
- AGE-RNAse refers to the advanced glycosylation endproducts which are formed upon chemical reaction of the substrates RNAse, Hb, BSA, HSA, albumin, collagen and LDL, respectively with a reducing sugar.
- AGE-RNAse refers to the advanced glycosylation endproducts of the reaction between bovine ribonuclease and a reducing sugar.
- Albumin when recited generically, refers to any species from which it was obtained, e.g., human, bovine, etc.
- BSA refers to bovine serum albumin.
- HSA refers to human serum albumin.
- RNAse refers to ribonuclease generally, and where appropriate, to bovine pancreatic ribonuclease in particular.
- Collagen is used in the conventional sense to refer to any type of collagen and derived from any appropriate source. When a specific type of collagen was used, such as in the example, the particular type is noted. However, it is recognized that alternative collagen types can also be used.
- FFI-BSA refers to a model AGE-protein produced by mixing 2-(2-furoyl)-4(5)J2-furanyl)-1 H_-imidazole hexanoic acid with bovine serum albumin and coupling the reactive compounds with dicyclohexylcarbodiimide.
- proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of these materials. Also, the terms "wound healing modulator” and “agent” are intended where appropriate, to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.
- an “antibody” is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope.
- the term encompasses, inter alia, polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,81 6,397 and 4,816,567.
- phrases “pharmaceutically acceptable” refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
- terapéuticaally effective amount is used herein in the qualitative sense to mean an amount sufficient to promote the healing of a non-healing wound. Quantitatively, this phrase means an amount sufficient to promote, and preferably accelerate by at least about 10 percent, more preferably by at least 20 percent, a clinically significant change in the rate or extent of wound healing as a result of the administration of the wound healing modulator of the present invention.
- the present invention concerns methods of diagnosing and treating wound healing dysfunction by resort to the identification and administration of certain modulators of wound healing, including certain agents represented in part by a class of compounds known as advanced glycosylation endproducts (AGEs) that are believed to take part in the promotion of wound healing.
- AGEs advanced glycosylation endproducts
- the present invention includes therapeutic methods employing the wound healing modulators identified herein and compositions containing the same for use in such methods.
- the wound healing modulators of the present invention comprising the agents, their homologs, similarly active drugs, their receptors, their binding partner(s) or other ligands or agents exhibiting either mimicry or antagonism to the agents or control over their production, may be prepared in pharmaceutical compositions, with a suitable carrier and at a strength effective for administration by various means to a patient having a tissue wound or a wound healing disorder or dysfunction, for the treatment thereof.
- compositions may be administered by parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, including delivery in an irrigation fluid used to wash body wound areas, catheterizations and the like.
- parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, including delivery in an irrigation fluid used to wash body wound areas, catheterizations and the like.
- Average quantities of the wound healing modulator may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.
- concentrations of the wound healing modulator may range from at least about 100 ng/cm 2 , and preferably from about 1 /g/cm 2 to about 10 ⁇ g/cm 2 may be used.
- concentrations of the wound healing modulator administered may vary and should be based upon the recommendations and prescription of a qualified physician or veterinarian.
- the materials that function as modulators of wound healing extend to the binding partners of the agents defined herein, and particularly include the antibodies, receptors, materials not antibodies to the agents that antagonize the production and/or wound healing modulating activity of the agents and other binding partners thereto.
- certain agents such as AGE-RNAse
- specific antibodies that would antagonize the modulating effect that they exert on wound healing could be identified.
- Antibodies including both polyclonal and monoclonal antibodies, and drugs may also be raised to the agent and may be utilized where appropriate for the purpose of modulating wound healing by a mammalian host.
- the agent may be used to produce antibodies to itself in a variety of animals, by known techniques such as the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells.
- the resulting antibodies could then be prepared in a suitable pharmaceutical composition and administered to the intended host.
- the exact quantities, intervals of administration and administrative techniques respecting such pharmaceutical compositions may vary in accordance with those known in the medical arts, and upon the specific instruction of a qualified physician or veterinarian.
- the agents may bind to particular naturally occurring binding activities including cell associated and soluble receptors to facilitate intracellular transmission of messages relating to wound healing activity, and these binding activities or receptor molecules may be identified as they form complexes with the agents, and thereafter may be isolated and prepared in sufficient quantities to be used in the same fashion as the agents themselves, to modulate wound healing activity.
- binding activities or receptor molecules may be identified as they form complexes with the agents, and thereafter may be isolated and prepared in sufficient quantities to be used in the same fashion as the agents themselves, to modulate wound healing activity.
- a variety of diverse receptor systems are known, such as the tyrosine kinases and G-protein receptors are already known and operate to transmit messages to the genetic material of the cell to cause corresponding changes in protein synthesis, and the present invention contemplates that these molecules and other functionally similar molecules, may participate in wound healing modulation in accordance herewith.
- the present invention also relates to a variety of diagnostic applications, including methods for detecting or investigating disorders or dysfunctions in wound healing by reference to the ability of the present wound healing modulators of the present invention comprising the agents and their binding partners to promote or inhibit wound healing activity.
- the agents or their binding partners could be appropriately labeled and placed in contact with a sample of wound inflammatory fluid, tissue or blood from a mammal in which the disorder is suspected. Thereafter, the sample could be examined to determine the location and status of the labeled material as well as the general activity of the sample, i.e. whether wound healing activity has increased or decreased.
- Solutions of purified AGE-collagen and collagen alone were prepared in vehicle from concentrated stocks (below) to the desired final concentrations. A 50 ⁇ drop of AGE-collagen- or collagen-vehicle or vehicle alone was applied to each wound, and spread over the wound with the tip of a sterile pipette.
- Wounds were individually sealed with a semipermeable dressing: Benzoin was applied as an adhesive to a zone of intact skin surrounding the perimeter of each wound and the wound was sealed with a patch of Opsite applied to cover the wound and extend over and adhere to the zone of Benzoin-treated intact skin surrounding each wound. Ops ⁇ te-sealed wounds were then covered with a bulky dressing.
- Biopsies of healing wounds were initially taken on days 3, 4 and 5 after wounding. Preliminary analysis of control wounds revealed that day 4 wounds were best suited to display differences in the rate or degree of healing, and day 4 biopsies were obtained from subsequent tests. Control wounds on day 4 typically show mild residual inflammation and fibroblast activity with persisting ulceration in the sense that epidermal regrowth is still incomplete and portions of the dermis remain exposed. Where epidermis is reforming from the margins of the wound and focally from the hair follicles spared by wounding, there is good granular layer formation with areas of overlying cornified epithelium and little parakeratosis. At this incompletely healed stage, then, a variety of histological characteristics of wound healing are intermediate.
- Acceleration or retardation of wound healing is manifest to a trained dermatopathologist by light microscopic comparison of histological sections prepared from biopsies of the healing wounds. Histological sections from wounds in which healing has been accelerated by treatment can be expected to have less remaining ulceration or even complete recoverage by epidermis with good granular layer formation and a more complete overlying cornified layer, and little or no residual fibroblast proliferation or parakeratosis. These histological criteria for completeness of healing can be expected to vary in the other direction if wound healing is retarded by treatment.
- test pigs were anesthetized as at wounding, wound dressings were removed, and the wounds photographed for gross characterization of healing. When fully anesthetized, test pigs were then overdosed with SleepAway euthanasia solution. Elliptical biopsy samples through the full skin thickness (into the layer of subcutaneous fat) and extending across the full width of the wound and into intact skin on either side were then cut from each wound by hand using a scalpel. Biopsy samples were individually fixed by immersion in 10% buffered formalin in coded containers which did not reveal what treatment the parent wound had received.
- Coded samples were then routinely processed for light microscopic histological analysis by sectioning at 5 ⁇ m, mounting on slides, and staining with hematoxyiin and eosin.
- the biopsies were cut into histological sections in a plane normal (perpendicular) to the surface of the skin, so as to include both the full extent of the wound and a small margin of non-wounded skin at each end of the section.
- the degree of wound healing was assessed by measuring the linear extent of re- epithelialization across the full width of the histological sections from the wound biopsy; that is, from the boundary of non-wounded skin on one side of the section to the boundary of non-wounded skin at the other side of the wound.
- Measurements were taken microscopically, by using a calibrated ocular reticule to measure the linear extent of the total wound, and the linear extent of re- epithelial ⁇ zed wound.
- the linear extent of re-epithel ⁇ alized wound was then expressed as a percentage of the linear extent of the total wound, and this percentage was taken as a measurement of the degree of wound healing.
- the sections taken 3 days after healing show a marked difference between tissue treated with AGE-collagen and that treated with unmodified collagen.
- the treated tissue shows completely healed epidermis, with full epithelialization overlying a slightly cellular dermis.
- the epidermis shows focally a good granular layer, and only minimal parakeratosis.
- the control tissue while fully epithelialized, still contains many fibroblasts within the dermis, and there is only poor granular layer formation. This suggests a much less advanced healing wound. Similar changes are seen in tissue taken 4 and 5 days post wounding.
- the tissue treated with AGE-coilagen consistently shows more mature appearing epidermis, with full granular and minimal overlying parakeratosis.
- the control sections, while almost completely epithelialized still show poor granular layer formation and extensive overlying parakeratosis.
- mice Male Lewis rats (350-450 g) were made diabetic by intravenous injection of streptozotocin (65 mg/kg). One week later, they were bled, and their plasma tested for glucose levels. Rats with glucose levels greater than 400 mg/dl were considered diabetic. Diabetic and non-diabetic rats were then divided into groups:
- the rats were anesthetized using a mixture of Xylazine and Ketamine (1 :9), given intramuscularly at a level of .001 mg/g body weight.
- the backs of the rats were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine.
- An incision of approximately 5 cm was made in the skin along the midline of the back.
- a subcutaneous continuous stitch was used to close the incision, using the appropriate suture lot.
- the incision sites were visually inspected on a daily basis to monitor healing.
- the animals were sacrificed at 14 days using C0 2 .
- the skin from their backs was removed, and evaluated visually as to how they have healed in comparison with the control groups.
- the extent of wound closure was evaluated, blinded to group, by three individuals and graded on a scale of 1 + to 3+ with 1 + being the least healed and 3 + being the best closure with little or no scar.
- the degree of vascularization was evaluated by examination of the underlying skin using a light box. This enabled the investigator to visualize by transmitted light the amount of blood vessels formed along the suture line.
- Vascularity was evaluated on a 1 + to 4+ scale with 1 + being little vascularity around the incision site and 4 + being the greatest degree of vascularity. All animals were coded so that the final evaluations were done blinded as to the treatment group.
- Rat # F had some pus oozing from incision TABLE C
- mice 25 non-diabetic male C 3 H/Hej mice (25-30g) were anesthetized as described above. Their backs were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine. An incision of approximately 2-2.5 cm was made in the skin along the midline of the back. A cutaneous interrupted stitch was used to close the incision, using either control silk sutures or AGE-silk sutures (incubated with ribose as described in Example 2). The animals were sacrificed 7 days later and the skin removed as described above. The closure could not be evaluated adequately in mice due to the thin nature of the skin and the dark color of the strain being tested. Therefore, only the degree of vascularity was assessed as described above. One obvious but unexpected occurrence in this study was related to the degree of new hair growth in mice whose wounds were closed using AGE sutures. These results are included in Table D, below. TABLE D
- the agents herein may be formulated for the treatment of a variety of mammals, including domestic and farm animals, as well as humans, to control the wound healing process, and where desired, to assist in its promotion and the promotion of tissue growth and reconstruction as described and as evidenced hereinabove.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the promotion of tissue turnover by the administration of one or more wound healing modulators. The wound healing modulator may be selected from appropriate wound healing agents and binding partners, and particularly agents that enhance wound healing. The agent may comprise advanced glycosylation endproducts (AGEs), compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof. The AGEs constituting agents may particularly comprise the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose and ribose; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof. Diagnostic and therapeutic utilities are proposed, the latter including the treatment of wound healing dysfunction, the promotion of transplant tissue acceptance and the promotion of hair growth. Pharmaceutical compositions and prosthetic materials are likewise contemplated and set forth.
Description
METHOD AND AGENTS FOR PROMOTING WOUND HEALING
RELATED PUBLICATIONS
The Applicants are co-authors of the following articles directed to the subject matter of the present invention:
"FUNCTION OF MACROPHAGE RECEPTOR FOR NONENZYMATICALLY GLYCOSYLATED PROTEINS IS MODULATED BY INSUUMJLΕVELS", Vlassara, Brownlee and Cerami, DIABETES (1986), Vol. 35 Supp. 1 , Page 13a; "ACCUMULATION OF DIABETIC RAT PERIPHERAL NERVE MYELIN BY MACROPHAGES INCREASES WITH THE PRESENCE OF ADVANCED GLYCOSYLATION ENDPRODUCTS", Vlassara, H., Brownlee, M., and Cerami, A. J. EXP. MED. (1984), Vol. 1 60, pp. 197-207; "RECOGNITION AND UPTAKE OF HUMAN DIABETIC PERIPHERAL NERVE MYELIN BY MACROPHAGES", Vlassara, H., Brownlee, M., and Cerami, A. DIABETES (1985), Vol. 34, No. 6, pp. 553- 557; "HIGH-AFFINITY-RECEPTOR-MEDIATED UPTAKE AND DEGRADATION OF GLUCOSE-MODIFIED PROTEINS: A POTENTIAL MECHANISM FOR THE REMOVAL OF SENESCENT MACROMOLECULES", Vlassara H., Brownlee, M., and Cerami, A., PROC. NATL. ACAD. SCI. U.S.A. (Sept. 1985), Vol. 82, pp. 5588-5592; "NOVEL MACROPHAGE RECEPTOR FOR GLUCOSE-MODIFIED PROTEINS IS DISTINCT FROM PREVIOUSLY DESCRIBED SCAVENGER RECEPTORS", Vlassara, H., Brownlee, M., and Cerami, A. JOUR. EXP. MED. (1986), Vol. 164, pp. 1301 -1309; "ROLE OF NONENZYMATIC GLYCOSYLATION IN ATHEROGENESIS", Cerami, A., Vlassara, H., and Brownlee, M., JOURNAL OF CELLULAR BIOCHEMISTRY (1986), Vol. 30, pp. 1 1 1-120; "CHARACTERIZATION OF A SOLUBILIZED CELL SURFACE BINDING PROTEIN ON MACROPHAGES SPECIFIC FOR PROTEINS MODIFIED NONENZYMATICALLY BY ADVANCED GLYCOSYLATION END PRODUCTS", Radoff, S., Vlassara, H. and Cerami, A., ARCH. BIOCHEM. BIOPHYS (1988), Vol. 263, No. 2, pp. 41 8-423; "ISOLATION OF A SURFACE BINDING PROTEIN SPECIFIC FOR ADVANCED GLYCOSYLATION ENDPRODUCTS FROM THE MURINE MACROPHAGE-DERIVED CELL LINE RAW 264.7", Radoff, S., Vlassara, H., and Cerami, A., DIABETES, (1990), Vol. 39, pp. 1510-1 518. All of the foregoing publications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
The present invention generally relates to the repair of damaged tissues in animals and particularly humans, and, more particularly, to the modulation of the healing of wounds in such tissue.
Injury to animal tissue resulting in tissue wounds occurs from an endless variety • of pathological and non-pathological causes. In response to injury, a variety of cells have been determined to cooperate to repair the damaged tissue and heal the wound. Cells resident in the local tissue participate, as do circulating blood cells specifically recruited into the wound itself and the area nearby. Dramatic changes in cellular function are required by both the resident and recruited cells in order to initiate, coordinate, and sustain the complex process of wound healing. Damaged cells and disrupted tissue matrix must be removed, new cells must be formed, and must grow and mature to replace those lost. The tissue matrix must be resynthesized and remodeled, and even the microvasculature may need to be rebuilt to supply the new tissue.
It is now recognized that cytokines exchanged among responding cells mediate the induction, control, and coordination of these and other cellular functions necessary to successfully heal the wound.
Recent interest and study of advanced glycosylation endproducts ("AGEs") has developed, and began with the observation that reducing sugars, e.g., glucose, react non-enzymatically with protein amino groups to form a diverse series of protein bound moieties with fluorescent and crosslinking properties. These compounds have been implicated in structural and functional alteration of proteins during aging and in certain diseases that are considered degradative and undesirable, e.g., the embrittlement of structural proteins observed in long-term diabetes. Several AGEs have been identified on the basis of de novo synthesis and tissue isolation procedures.
In Parent Application Serial No. 907,747 and in applications following therefrom, the use of AGEs and other agents for the recognition and removal of jn vivo
resident advanced glycosylation endproducts was disclosed. The admipinstration of these agents, however, was for the essentially catabolic purpose of mobilizing the macrophage to recognize and remove AGEs. Since AGEs accumulate in pathological states, it was not apparent what role AGEs might play in the promotion and facilitation of wound healing. It is therefore to this determination and other discoveries that the present Application is directed.
SUMMARY OF THE INVENTION
In accordance with the present invention, diagnostic and therapeutic protocols are proposed that are predicated in part on the discovery that advanced glycosylation endproducts (AGEs) and other agents previously described for the promotion of the vivo recognition and removal of AGEs, possess a definitive modulating effect upon the progression of tissue reconstruction and wound healing in mammals, and are capable of stimulating and promoting both activities.
Accordingly, the present invention relates in its broadest aspect to the treatment of wounds as well as various wound healing dysfunctions by the administration of a wound healing modulator comprising a material selected from the group consisting of agents capable of modulating wound healing, binding partners thereto, and the muteins and fragments thereof, wherein the agents are selected from advanced glycosylation endproducts (AGEs), compositions and complexes containing advanced glycosylation endproducts alone or bound to a carrier, derivatives thereof, and mixtures thereof. The carrier may include a material selected from carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof. The agent could include other advanced glycosylation endproducts that may be prepared synthetically or from the reaction between sugars and other macromolecules, and monokines which stimulate phagocytic cells to increase their activity toward advanced glycosylation endproducts.
Accordingly, the agent may comprise the compounds FFI or AFGP bound to a protein such as albumin. Alternately, the agent may comprise a synthetically
derived advanced glycosylation endproduct which is prepared, for example, by the reaction of glucose or glucose-6-phosphate with albumin. This reaction product can be used alone or with a carrier in the same fashion as the FF1- albumin complex.
A monokine that functions as an agent comprises the protein known as Tumor Necrosis Factor (TNF) and its variant discovered and isolated by one of the inventors herein and named "cachectin". This material may be administered alone or in conjunction with other agents.
In addition, the agents of the present invention may be administered in conjunction with materials identified hereinafter as "co-stimulatory" agents. The coadmϊnistration of the agent with the co-stimulatory agents has been found to potentiate the activity of the former. Suitable co-stimulatory agents include monokines such as lnterleukin-1 (IL-1 ) and gamma-interferon.
Particular therapeutic applications contemplate the administration of the wound healing modulators to specific tissues and organs to promote tissue remodelling and reconstruction. For example, AGEs useful in accordance herewith may be introduced to particular tissues by injection to stimulate and promote cellular growth or regrowth, in some instances, that will result in the structural and functional enhancement of the treated tissues.
The growth stimulating effect of the modulators of the invention finds a further application in the promotion of tissue acceptance and the corresponding limitation or inhibition of tissue rejection in tissue transplantation and reconstruction. For example, fibers implanted to promote tissue regrowth, transplanted organs or synthetic organs prepared in some instances, at least in part from structural proteinaceous material such as collagen, may have applied to them one or more of the present wound healing modulators before implantation, to promote acceptance of the exogenous material and incorporation into the target tissue. The modulators in this instance may be bound to the protein or may be otherwise adherently applied as a coating by known techniques. Accordingly, the invention extends to the corresponding
prosthetic materials having the modulators applied as a coating thereto, or chemically linked by known methods such as for example, coupling thereto a synthetic AGE such as FFI-BSA or the like.
Another application of the modulators of the present invention derives from the observations presented below, that the application of the wound healing modulator to skin stimulates hair growth. It is apparent from this that the stimulation of hair growth may be achieved by the topical or intradermal application of the present modulators, and the present invention accordingly extends to a method of stimulating hair growth thereby. This method may comprise the local application of the modulator to the dermal area, with the formulation of the modulator dosage contemplating both topical applications and if appropriate, dermal implants or injections.
The AGEs that may serve as agents may comprise the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose and ribose; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof. Particularly, the agent may comprise an advanced glycosylation endproduct selected from the group consisting of the chromophores 2-(2-furoyl)-4(5)-(2-furanyl)-1 H_-imidazole (FFI), 1 -alkyl-2-formyl-3,4-diglycosyl-pyrrole (AFGP), alone and coupled to carriers such as BSA, HSA, and avidin.
Suitable agents also include materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity, such as homologous agents derived synthetically or from other cellular sources or from other species. The agent binding partners contemplated by the invention include anti-agent antibodies, receptors for the agents, materials not antibodies that antagonize the production and/or wound healing modulating activity of the agents, binding partners thereto, and other binding partners thereof. The present wound healing modulators may comprise materials that are capable of acting in vivo, and in a further embodiment, may be promoters of wound healing.
The invention accordingly includes a method for promoting wound healing comprising administering an effective amount of one of the above wound healing modulators individually, or in mixture with each other or formulated as a pharmaceutical composition. More particularly, the modulators contemplated for use in this method comprise those agents and binding partners that act as promoters of wound healing, and extend for example, to homologous agents derived from other cellular sources or from other species, materials capable of promoting agent production and/or activity, and materials capable of mimicking agent activity.
Pharmaceutical compositions may be prepared in accordance with the invention and comprise therapeutically effective amounts of the present wound healing modulators, either alone or in admixture with each other, and a pharmaceutically acceptable diluent or carrier. The modulators may preferably be present in amounts effective to deliver at least 100 ng/cm2 and preferably from about 1 μgfcm2 to about 10 g/cm2 thereof.
The therapeutic methods of the present invention apply generally to mammals and contemplate veterinary use as well as application to humans. The particular therapeutic protocols will vary accordingly upon the subject of treatment.
In the instance where wound healing may be beneficially monitored, such as to identify suspected disorders affecting wound healing, the present invention contemplates a method for measuring the activity of the wound healing modulators of the present invention. The method comprises retrieving a sample of wound fluid which such disorder is suspected, and incubating the sample with a quantity of a wound healing modulator of the present invention bearing an appropriate detectable label. The sample may thereafter be examined to determine whether such aberrant cellular activity is due to a deficiency in wound healing factor presence or activity, and to thereby attempt to isolate and identify the cause of such disorder. The present invention may also extend to appropriate new drug assays and test kits including the wound healing modulators of the present invention.
Accordingly, it is a principal object of the present invention to provide a method for treating wound healing dysfunctions in mammals.
It is a further object of the present invention to provide a method as aforesaid that is applicable to the promotion of tissue turnover and wound healing.
It is a yet further object of the present invention to provide pharmaceutical compositions for use in therapeutic methods for treating wound healing dysfunctions and/or promoting wound healing which comprise or are based upon certain wound healing modulators including agents and their binding partner(s).
It is a still further object of the present invention to provide a method for promoting wound healing by the administration of the pharmaceutical composition as aforesaid.
It is a still further object of the present invention to provide a method for promoting hair growth by the topical application of the modulators of the present invention as aforesaid.
It is a still further object of the present invention to provide a method for promoting implant acceptance and incorporation by the application to the implant material prior to implantation of the wound healing modulators as aforesaid.
It is a further object of the present invention to provide a method for measuring the activity of the wound healing modulators as aforesaid, that also serves to evaluate possible disorders in wound healing.
Other objects and advantages will become apparent to those skilled in the art from a review of the ensuing description.
DETAILED DESCRIPTION
In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. Therefore, if appearing herein, the following terms shall have the definitions set out below. The term "stimulus" and its plural as used herein are intended to apply to invasive events such as infection, as well as conditions caused by wounding, and to idiopathϊc or spontaneous states that may for example, originate from cellular or metabolic derangements or other causes.
The terms "wound healing modulator", "agent", "AGE" and "AGEs" as used throughout the present application and claims refer to protein material having the profile of activities set forth herein and in the Claims. The terms "AGE" and "AGEs" are used as appropriate to refer to advanced glycosylation endproducts which are in the form of stable compounds and intermediates which are produced synthetically, ]n vivo, and ]n vitro by the reaction of reducing sugars with protein amino groups. AGEs therefore encompass intermediates as well as stable endproducts that are implicated in the structural and functional alteration of proteins seen during aging. For example, AGEs are recognized to react with free polypeptide amino groups, which leads to protein crosslinking. Additionally, such AGES are observed in elevated levels in circulation and in tissues in certain diseases, e.g. diabetes mellitus.
When the designations "AGE-RNAse", "AGE-Hb", "AGE-BSA", "AGE-HSA", "AGE-albumin", "AGE-coIlagen" and "AGE-LDL" are used, each refers to the advanced glycosylation endproducts which are formed upon chemical reaction of the substrates RNAse, Hb, BSA, HSA, albumin, collagen and LDL, respectively with a reducing sugar. Thus, AGE-RNAse refers to the advanced glycosylation endproducts of the reaction between bovine ribonuclease and a reducing sugar.
Albumin, when recited generically, refers to any species from which it was obtained, e.g., human, bovine, etc.
BSA refers to bovine serum albumin.
HSA refers to human serum albumin.
RNAse refers to ribonuclease generally, and where appropriate, to bovine pancreatic ribonuclease in particular.
Collagen is used in the conventional sense to refer to any type of collagen and derived from any appropriate source. When a specific type of collagen was used, such as in the example, the particular type is noted. However, it is recognized that alternative collagen types can also be used.
Where present, the term "FFI-BSA" refers to a model AGE-protein produced by mixing 2-(2-furoyl)-4(5)J2-furanyl)-1 H_-imidazole hexanoic acid with bovine serum albumin and coupling the reactive compounds with dicyclohexylcarbodiimide.
Accordingly, proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of these materials. Also, the terms "wound healing modulator" and "agent" are intended where appropriate, to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.
An "antibody" is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope. The term encompasses, inter alia, polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,81 6,397 and 4,816,567.
The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an
allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
The phrase "therapeutically effective amount" is used herein in the qualitative sense to mean an amount sufficient to promote the healing of a non-healing wound. Quantitatively, this phrase means an amount sufficient to promote, and preferably accelerate by at least about 10 percent, more preferably by at least 20 percent, a clinically significant change in the rate or extent of wound healing as a result of the administration of the wound healing modulator of the present invention.
In its primary aspect, the present invention concerns methods of diagnosing and treating wound healing dysfunction by resort to the identification and administration of certain modulators of wound healing, including certain agents represented in part by a class of compounds known as advanced glycosylation endproducts (AGEs) that are believed to take part in the promotion of wound healing.
As discussed earlier, the present invention includes therapeutic methods employing the wound healing modulators identified herein and compositions containing the same for use in such methods. Accordingly, the wound healing modulators of the present invention comprising the agents, their homologs, similarly active drugs, their receptors, their binding partner(s) or other ligands or agents exhibiting either mimicry or antagonism to the agents or control over their production, may be prepared in pharmaceutical compositions, with a suitable carrier and at a strength effective for administration by various means to a patient having a tissue wound or a wound healing disorder or dysfunction, for the treatment thereof.
A variety of administrative techniques may be utilized, among them topical applications as in ointments or on surgical and other topical appliances such as, surgical sponges, bandages, gauze pads, and the like. Also, such compositions may be administered by parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, including delivery in an irrigation fluid
used to wash body wound areas, catheterizations and the like. Average quantities of the wound healing modulator may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.
In particular, concentrations of the wound healing modulator may range from at least about 100 ng/cm2, and preferably from about 1 /g/cm2 to about 10 μg/cm2 may be used. The exact quantities of the wound healing modulator administered may vary and should be based upon the recommendations and prescription of a qualified physician or veterinarian.
As mentioned earlier, the materials that function as modulators of wound healing extend to the binding partners of the agents defined herein, and particularly include the antibodies, receptors, materials not antibodies to the agents that antagonize the production and/or wound healing modulating activity of the agents and other binding partners thereto. In the instance of certain agents such as AGE-RNAse, specific antibodies that would antagonize the modulating effect that they exert on wound healing could be identified.
Antibodies, including both polyclonal and monoclonal antibodies, and drugs may also be raised to the agent and may be utilized where appropriate for the purpose of modulating wound healing by a mammalian host. In particular, the agent may be used to produce antibodies to itself in a variety of animals, by known techniques such as the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells. The resulting antibodies could then be prepared in a suitable pharmaceutical composition and administered to the intended host. The exact quantities, intervals of administration and administrative techniques respecting such pharmaceutical compositions may vary in accordance with those known in the medical arts, and upon the specific instruction of a qualified physician or veterinarian.
Similarly, the agents may bind to particular naturally occurring binding activities including cell associated and soluble receptors to facilitate intracellular transmission of messages relating to wound healing activity, and these binding
activities or receptor molecules may be identified as they form complexes with the agents, and thereafter may be isolated and prepared in sufficient quantities to be used in the same fashion as the agents themselves, to modulate wound healing activity. By way of illustration and not limitation, a variety of diverse receptor systems are known, such as the tyrosine kinases and G-protein receptors are already known and operate to transmit messages to the genetic material of the cell to cause corresponding changes in protein synthesis, and the present invention contemplates that these molecules and other functionally similar molecules, may participate in wound healing modulation in accordance herewith.
The present invention also relates to a variety of diagnostic applications, including methods for detecting or investigating disorders or dysfunctions in wound healing by reference to the ability of the present wound healing modulators of the present invention comprising the agents and their binding partners to promote or inhibit wound healing activity. As mentioned earlier, the agents or their binding partners could be appropriately labeled and placed in contact with a sample of wound inflammatory fluid, tissue or blood from a mammal in which the disorder is suspected. Thereafter, the sample could be examined to determine the location and status of the labeled material as well as the general activity of the sample, i.e. whether wound healing activity has increased or decreased.
As indicated earlier, the following examples set forth the details of the investigation and identification of the wound healing promoting activity of the stated inflammatory cytokines. Naturally, the specific materials and techniques set forth hereinafter are exemplary only and may vary, so that the following is presented as illustrative but not restrictive of the present invention.
EXAMPLE 1
Promotion of Wound Healing in vivo bv AGEs
This series of experiments sought to determine whether advanced glycosylation endproducts such as AGE-collagen tested herein were involved in any way in
promoting wound healing. Accordingly, AGE-collagen and unmodified collagen were assessed in a standard porcine model of wound healing in response to partial thickness skin injury.
Materials and Methods
Surgical Wounding
The wound healing model used in these studies is a modification of that described by Eaglstein and co-workers ("New Method for Assessing Wound Healing: The Effects of Triamcinolone Acetonide and Polyethylene Film
Occlusion," J. of Invest. Derm.. 71:382-384, 1978). Young White Yorkshire pigs weighing 10-15 kg were used all wounding experiments. Anesthesia was induced in the following manr. Pigs received pre-operative medication with Azaperone (1 mg/lb), Atropine (0.04 mg/kg) and Ketamine (10 mg/kg) by s.m. injection. Animals were then taken to the surgical suite, intut ed and maintained under Isofluorane inhalation anesthesia and re rous oxicu at 1 .5 L/min. The animals w .ι _, liven supplemental oxygen during the procedure and maintained on a warning banket.
Once adequate anesthesia had been attained, the back ar dorsal t A ax of the pigs was shaved and prepared with a 70% alcohol solutiϋ . Tempa.ature was monitored throughout the operation, and an i.v. line (started after the animal was asleep) was maintained. Depth of anesthesia was monitored by corneal reflexes and withdrawal to painful stimuli. Anesthesia was titrated to maintain an unresponsive state. Partial thickness epidermal wounds were then made with a Padgett dermatome to a depth of 0.01 5 inches. Wounds were 2 x 5 cm in area. This type of injury, which removes the epidermis and a zone of the superficial dermis but spares the hair follicles, has been previously shown to be comparable to a second degree burn injury or a donor site for a skin graft.
Once all of the wounds had been created (eight pairs of wounds were made, one wound of each pair on each side of the midline), the wounds were treated and dressed. The animals were then allowed to emerge from anesthesia and
monitored closely for pain. Pain was treated with Demerol (10 mg/kg i.m.) every 4-6 hours as needed.
Treatment of Wounds Partial thickness cutaneous wounds were treated in pairs; one wound of each pair was treated with AGE-collagen in vehicle (PBS), the other treated with an amount of collagen alone in vehicle. Wounds were treated in a pattern of bilateral pairs, whereby every AGE-collagen treated wound was matched to a contralaterally corresponding wound treated with collagen alone, at the same location on the other side of the midline of the back.
Solutions of purified AGE-collagen and collagen alone, were prepared in vehicle from concentrated stocks (below) to the desired final concentrations. A 50 μ\ drop of AGE-collagen- or collagen-vehicle or vehicle alone was applied to each wound, and spread over the wound with the tip of a sterile pipette.
Wounds were individually sealed with a semipermeable dressing: Benzoin was applied as an adhesive to a zone of intact skin surrounding the perimeter of each wound and the wound was sealed with a patch of Opsite applied to cover the wound and extend over and adhere to the zone of Benzoin-treated intact skin surrounding each wound. Opsϊte-sealed wounds were then covered with a bulky dressing.
Dosages Wounds were treated with AGE-collagen/collagen at the time of wounding and daily thereafter, at various dosages from 1 to 10 μg AGE-collagen or unmodified collagen per 50 μ\ vehicle (PBS) per wound. Because wounds measured approximately 2 x 5 cm, this dosage corresponds to 0.1 to 1 μg AGE-collagen or unmodified collagen per cm2 wound area, respectively.
Biopsy Technioue and Histolooical Analysis
Biopsies of healing wounds were initially taken on days 3, 4 and 5 after wounding. Preliminary analysis of control wounds revealed that day 4 wounds were best suited to display differences in the rate or degree of healing, and day
4 biopsies were obtained from subsequent tests. Control wounds on day 4 typically show mild residual inflammation and fibroblast activity with persisting ulceration in the sense that epidermal regrowth is still incomplete and portions of the dermis remain exposed. Where epidermis is reforming from the margins of the wound and focally from the hair follicles spared by wounding, there is good granular layer formation with areas of overlying cornified epithelium and little parakeratosis. At this incompletely healed stage, then, a variety of histological characteristics of wound healing are intermediate.
Acceleration or retardation of wound healing is manifest to a trained dermatopathologist by light microscopic comparison of histological sections prepared from biopsies of the healing wounds. Histological sections from wounds in which healing has been accelerated by treatment can be expected to have less remaining ulceration or even complete recoverage by epidermis with good granular layer formation and a more complete overlying cornified layer, and little or no residual fibroblast proliferation or parakeratosis. These histological criteria for completeness of healing can be expected to vary in the other direction if wound healing is retarded by treatment.
To assess the rate and completeness of healing, test pigs were anesthetized as at wounding, wound dressings were removed, and the wounds photographed for gross characterization of healing. When fully anesthetized, test pigs were then overdosed with SleepAway euthanasia solution. Elliptical biopsy samples through the full skin thickness (into the layer of subcutaneous fat) and extending across the full width of the wound and into intact skin on either side were then cut from each wound by hand using a scalpel. Biopsy samples were individually fixed by immersion in 10% buffered formalin in coded containers which did not reveal what treatment the parent wound had received. Coded samples were then routinely processed for light microscopic histological analysis by sectioning at 5 μm, mounting on slides, and staining with hematoxyiin and eosin. The biopsies were cut into histological sections in a plane normal (perpendicular) to the surface of the skin, so as to include both the full extent of the wound and a small margin of non-wounded skin at each end of the section.
The degree of wound healing was assessed by measuring the linear extent of re- epithelialization across the full width of the histological sections from the wound biopsy; that is, from the boundary of non-wounded skin on one side of the section to the boundary of non-wounded skin at the other side of the wound. Measurements were taken microscopically, by using a calibrated ocular reticule to measure the linear extent of the total wound, and the linear extent of re- epithelialϊzed wound. The linear extent of re-epithelϊalized wound was then expressed as a percentage of the linear extent of the total wound, and this percentage was taken as a measurement of the degree of wound healing.
RESULTS The sections taken 3 days after healing show a marked difference between tissue treated with AGE-collagen and that treated with unmodified collagen. The treated tissue shows completely healed epidermis, with full epithelialization overlying a slightly cellular dermis. The epidermis shows focally a good granular layer, and only minimal parakeratosis. The control tissue, while fully epithelialized, still contains many fibroblasts within the dermis, and there is only poor granular layer formation. This suggests a much less advanced healing wound. Similar changes are seen in tissue taken 4 and 5 days post wounding. The tissue treated with AGE-coilagen consistently shows more mature appearing epidermis, with full granular and minimal overlying parakeratosis. The control sections, while almost completely epithelialized, still show poor granular layer formation and extensive overlying parakeratosis.
EXAMPLE 2
In this series of experiments, the healing properties of silk sutures reacted with sugar in order to produce AGEs were investigated. The following protocol was followed.
Rat Study Design:
Male Lewis rats (350-450 g) were made diabetic by intravenous injection of streptozotocin (65 mg/kg). One week later, they were bled, and their plasma
tested for glucose levels. Rats with glucose levels greater than 400 mg/dl were considered diabetic. Diabetic and non-diabetic rats were then divided into groups:
TABLE A Unbrowned sutures Sutures browned with ribose
Normal Controls 5 5
Diabetics 5 5
Two lots of silk sutures (Davis and Geek, Danbury, CT) were tested; untreated sutures and AGE-modified sutures. AGE-modified sutures were prepared by incubating the sutures in 200 mM ribose in 100 mM phosphate buffer, pH 7.4 for 2 weeks. The sutures were rinsed in PBS prior to use. There were 5 normal control rats for each suture lot, and 5 diabetic rats for each lot, for a total of 20 rats. (See Table A, below)
For implantation of sutures, the rats were anesthetized using a mixture of Xylazine and Ketamine (1 :9), given intramuscularly at a level of .001 mg/g body weight. The backs of the rats were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine. An incision of approximately 5 cm was made in the skin along the midline of the back. A subcutaneous continuous stitch was used to close the incision, using the appropriate suture lot. The incision sites were visually inspected on a daily basis to monitor healing. The animals were sacrificed at 14 days using C02. The skin from their backs was removed, and evaluated visually as to how they have healed in comparison with the control groups.
The extent of wound closure was evaluated, blinded to group, by three individuals and graded on a scale of 1 + to 3+ with 1 + being the least healed and 3 + being the best closure with little or no scar. The degree of vascularization was evaluated by examination of the underlying skin using a light box. This enabled the investigator to visualize by transmitted light the amount of blood vessels formed along the suture line. Vascularity was evaluated on a 1 + to 4+ scale with 1 + being little vascularity around the incision site and 4 +
being the greatest degree of vascularity. All animals were coded so that the final evaluations were done blinded as to the treatment group.
TABLE B
WOUND HEALING PROPERTIES OF AGE TREATED SUTURES OBSERVATIONS AT SACRIFICE
Closure
1 + = not healed well
2 + = healed well
3 + = healed very well; little or no scar
Vascularity
1 + = little or no vascularity around incision site
2 + = some vascularity around incision site
3 + = moderate vascularity around incision site
4 + = large amounts of vascularity around incision site
Rat # F had some pus oozing from incision
TABLE C
SUMMARY OF WOUND HEALING DATA:
% of Rats in Each Category
EXAMPLE 3
Mouse Study Design
25 non-diabetic male C3H/Hej mice (25-30g) were anesthetized as described above. Their backs were shaved, washed with soap and water, sprayed with alcohol, and swabbed with Provadine. An incision of approximately 2-2.5 cm was made in the skin along the midline of the back. A cutaneous interrupted stitch was used to close the incision, using either control silk sutures or AGE-silk sutures (incubated with ribose as described in Example 2). The animals were sacrificed 7 days later and the skin removed as described above. The closure could not be evaluated adequately in mice due to the thin nature of the skin and the dark color of the strain being tested. Therefore, only the degree of vascularity was assessed as described above. One obvious but unexpected occurrence in this study was related to the degree of new hair growth in mice whose wounds were closed using AGE sutures. These results are included in Table D, below.
TABLE D
WOUND HEALING PROPERTIES OF AGE SUTURES IN MICE
Animal Group Sutures Number of Mice in Each Category (% of Total) Number of Mice Vascularization" Showing An Increase in Hair
1 + 2 + 3 + 4 + Growth on Back
Normal Control 5 5 (33.3%) 3 (20%) 2 (13.3%) 1 (6.6%) Sutures (33.3%) (n = 15)
10 ro
Normal AGE-Sutures 0 (0%) 2 (20%) 4 (40%) 4 (40%) 7 (70%) (n = 10)
" See Table B for evaluation code
As indicated by the above data, the application of AGE to the skin in this fashion resulted in the promotion of hair growth. While the data shown is preliminary in nature, it clearly demonstrates this activity, and by virtue of its presence in an animal model that is considered credibly predictive of behavior in higher species, lends support to the application of the wound healing agents of the invention to this cosmetically constructive activity.
As indicated earlier, the agents herein may be formulated for the treatment of a variety of mammals, including domestic and farm animals, as well as humans, to control the wound healing process, and where desired, to assist in its promotion and the promotion of tissue growth and reconstruction as described and as evidenced hereinabove.
This invention may be embodied in other forms or carried out in other ways without departing from the spirit or essential characteristics thereof. The present disclosure is therefore to be considered as in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended Claims- and all changes which come within the meaning and range of equivalency are intended to be embraced therein.
Claims
1. A method of treating wound healing dysfunction and/or promoting wound healing in mammals including humans, comprising administering to a mammal a therapeutically effective amount of a wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
2. The method of Claim 1 wherein said agent is bound to a carrier.
3. The method of Claim 2 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
4. The method of Claim 1 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
5. The method of Claim 1 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
6. The method of Claim 1 wherein said wound healing modulator is selected from the group consisting of said agent, homologous agents derived from other cellular sources, homologous agents derived from other species, materials capable of promoting agent production and/or activity, materials capable of mimicking agent activity, muteins and fragments thereof, and mixtures thereof.
7. The method of Claim 1 wherein said binding partners to said agent are selected from the group consisting of anti-agent antibodies, a receptor for the agent, a material not antibody to the agent that antagonizes the production and/or wound healing modulating activity of the agent, and mixtures thereof.
8. The method of Claim 1 wherein said agent is derived from cells which are produced by recombinant DNA technologies.
9. The method of Claim 1 wherein said agent is administered in a concentration of at least about 100 ng/cm2 of wound area.
10. The method of Claim 1 wherein said agent is administered in a concentration of from about 1 μg to about 10 μg/cm2 of wound area.
1 1 . A pharmaceutical composition for the treatment of wound healing dysfunction and/or for promoting wound healing in mammals, including humans, comprising: A. a pharmaceutically effective amount of a wound healing modulator comprising a material selected from the group consisting of an agent for modulating wound healing, homologous agents derived from other cellular sources, homologous agents derived from other species, a material capable of promoting agent production and/or activity, a material capable of mimicking agent activity, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof; and B. a pharmaceutically acceptable carrier.
12. The composition of Claim 1 1 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
13. The composition of Claim 1 1 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
14. The composition of Claim 1 1 wherein said agent is present in an amount of at least about 100 ng dose.
15. The composition of Claim 1 1 wherein said agent is present in an amount of from about 1 μg/dose to about 10 μg/dose.
16. The composition of Claim 1 1 wherein said agent is derived from cells which are produced by genetic replication.
17. An antibody to an agent for modulating wound healing, wherein the agent to which said antibody is raised comprising is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
18. The antibody of Claim 17 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
19. The antibody of Claim 17 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
20. The antibody of Claims 1 7, 18 or 19 wherein said agent is derived from cells which are produced by genetic replication.
21. A method for detecting a disorder in wound healing in a mammal comprising measuring the activity of a wound healing modulator selected from the group consisting of an agent for modulating wound healing, homologous agents derived from other cellular sources, homologous agents derived from other species, a material capable of promoting agent production and/or activity, a material capable of mimicking agent activity, an anti-agent antibody, a receptor for the agent, a material not antibody to the agent that antagonizes the production and/or wound healing modulating activity of the agent, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof, said method for detecting comprising: A. preparing at least one sample of said agent; B. placing a detectable label on said agent sample; C. placing the labeled agent sample in contact with a tissue sample from a wound from said mammal in which disorder is suspected; and D. examining said tissue sample to locate said labeled material, and measuring to determine the activity of said agent.
22. The method of Claim 21 wherein said agent is bound to a carrier.
23. The method of Claim 22 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
24. The method of Claim 21 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
25. The method of Claim 21 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
26. The method of Claims 21 -24 or 25 wherein said agent is derived from cells which are produced by recombinant DNA technology.
27. A method for stimulating hair growth on a particular area of the body surface of a mammal comprising administering to said area an effective amount of a wound healing modulator, said wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
28. The method of Claim 27 wherein said agent is bound to a carrier.
29. The method of Claim 28 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
30. The method of Claim 27 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
31. The method of Claim 27 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
32. A method for promoting host acceptance and incorporation of transplanted tissue and suture material comprising applying to said tissue and suture material an effective amount of a wound healing modulator, said wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
33. The method of Claim 32 wherein said agent is bound to a carrier.
34. The method of Claim 33 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio- compatible natural and synthetic resins, antigens, and mixtures thereof.
35. The method of Claim 32 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, gIucose-6- phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
36. The method of Claim 32 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
37. A prosthetic implant comprising a biocompatible material selected from organ tissue and synthetic suture material, said biocompatible material having applied thereto an effective amount of a wound healing modulator, said wound healing modulator comprising a material selected from the group consisting of an agent for enhancing wound healing, binding partners thereto, and muteins and fragments thereof, wherein said agent is selected from the group consisting of advanced glycosylation endproducts, compositions and complexes containing advanced glycosylation endproducts, derivatives thereof, and mixtures thereof.
38. The prosthetic implant of Claim 37 wherein said agent is bound to a carrier.
39. The prosthetic implant of Claim 38 wherein said carrier is selected from the group consisting of carbohydrates, proteins, synthetic polypeptides, lipids, bio-compatible natural and synthetic resins, antigens, and mixtures thereof.
40. The prosthetic implant of Claim 37 wherein said agent comprises the reaction product of a sugar selected from the group consisting of glucose, glucose-6-phosphate, fructose, ribose, and mixtures thereof; and a protein selected from the group consisting of collagen, albumin, ribonuclease, avidin, and mixtures thereof.
41 . The prosthetic implant of Claim 37 wherein said agent comprises an advanced glycosylation endproduct selected from the group consisting of FFI and AFGP alone; FFI and AFGP coupled to a carrier selected from BSA, HSA, and avidin; and mixtures thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84138392A | 1992-02-25 | 1992-02-25 | |
| US07/841,383 | 1992-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993016717A1 true WO1993016717A1 (en) | 1993-09-02 |
Family
ID=25284734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/001677 WO1993016717A1 (en) | 1992-02-25 | 1993-02-25 | Method and agents for promoting wound healing |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU3733293A (en) |
| WO (1) | WO1993016717A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854221A (en) * | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
| US5945403A (en) * | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| US6024688A (en) * | 1996-03-08 | 2000-02-15 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| WO2001091773A3 (en) * | 2000-05-31 | 2002-05-02 | Encelle Inc | Method of stimulating hair growth |
| EP1319392A3 (en) * | 2001-12-12 | 2003-08-27 | Beiersdorf AG | Melanine-forming hair dye |
| WO2010063678A3 (en) * | 2008-12-01 | 2011-12-29 | Henkel Ag & Co. Kgaa | Novel deodorants and antiperspirants having hair growth inhibiting effect |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0157359A2 (en) * | 1984-04-02 | 1985-10-09 | National Jewish Hospital and Research Center | Collagen matrix for tissue repair |
| EP0259893A2 (en) * | 1986-09-12 | 1988-03-16 | The Rockefeller University | Agents for removing advanced glycosylation endproducts |
| WO1990000060A1 (en) * | 1988-06-30 | 1990-01-11 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| WO1993004086A1 (en) * | 1991-08-23 | 1993-03-04 | The Rockefeller University | Receptors for advanced glycosylation endproducts and uses thereof |
-
1993
- 1993-02-25 WO PCT/US1993/001677 patent/WO1993016717A1/en active Application Filing
- 1993-02-25 AU AU37332/93A patent/AU3733293A/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0157359A2 (en) * | 1984-04-02 | 1985-10-09 | National Jewish Hospital and Research Center | Collagen matrix for tissue repair |
| EP0259893A2 (en) * | 1986-09-12 | 1988-03-16 | The Rockefeller University | Agents for removing advanced glycosylation endproducts |
| WO1990000060A1 (en) * | 1988-06-30 | 1990-01-11 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| WO1993004086A1 (en) * | 1991-08-23 | 1993-03-04 | The Rockefeller University | Receptors for advanced glycosylation endproducts and uses thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6024688A (en) * | 1996-03-08 | 2000-02-15 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| US6521439B2 (en) | 1996-03-08 | 2003-02-18 | The Children's Medical Center Corporation | Nucleic acids encoding plasminogen fragments |
| US5854221A (en) * | 1996-12-12 | 1998-12-29 | The Children's Medical Center Corporation | Endothelial cell proliferation inhibitor and method of use |
| US5945403A (en) * | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| WO2001091773A3 (en) * | 2000-05-31 | 2002-05-02 | Encelle Inc | Method of stimulating hair growth |
| US6992062B2 (en) | 2000-05-31 | 2006-01-31 | Encelle, Inc. | Method of stimulation hair growth |
| US7700660B2 (en) | 2000-05-31 | 2010-04-20 | Encelle, Inc. | Method of treating chronic ulcers |
| EP1319392A3 (en) * | 2001-12-12 | 2003-08-27 | Beiersdorf AG | Melanine-forming hair dye |
| WO2010063678A3 (en) * | 2008-12-01 | 2011-12-29 | Henkel Ag & Co. Kgaa | Novel deodorants and antiperspirants having hair growth inhibiting effect |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3733293A (en) | 1993-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Herndon et al. | Characterization of growth hormone enhanced donor site healing in patients with large cutaneous burns | |
| Hrynyk et al. | Insulin and wound healing | |
| DE69111919T2 (en) | METHOD FOR SUPPRESSING THE ANGIOGENESIS OF TUMORS. | |
| Nanney et al. | Immunolocalization of epidermal growth factor receptors in normal developing human skin | |
| D'Amore | Mechanisms of retinal and choroidal neovascularization. | |
| DE69729125T2 (en) | TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS | |
| CA2079585C (en) | Ligand for the neu gene product | |
| DE69629826T2 (en) | THERAPEUTIC ANTIANGIOGENIC COMPOSITIONS AND METHODS | |
| US5137875A (en) | Hyaluronic acid-containing aqueous solution or aqueous dispersion of collagen | |
| EP0579626A1 (en) | Method and agents for promoting wound healing | |
| AU654574B2 (en) | Collagen film drug delivery for proteins | |
| DE60029304T2 (en) | ACTIVATION OF REGULATORY T CELLS THROUGH AN ALPHA MELANOCYTE STIMULATING HORMONE | |
| US5616562A (en) | Methods and compositions using substance P to promote wound healing | |
| AU2004203732A1 (en) | Uses of HMGB, HMGN, HMGA proteins | |
| King Jr et al. | Epidermal growth factor/transforming growth factor alpha receptors and psoriasis | |
| Zhou et al. | Hydrogels derived from acellular porcine corneal stroma enhance corneal wound healing | |
| Hanneken et al. | Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid. | |
| US7837993B2 (en) | Methods and compositions for regeneration of aged skeletal muscle tissues | |
| WO1993016717A1 (en) | Method and agents for promoting wound healing | |
| Leibowitz et al. | Effect of topically administered epidermal growth factor on corneal wound strength | |
| JP2002542824A (en) | Recombinant laminin 5 | |
| US6703363B1 (en) | Recombinant laminin 5 | |
| Taherzadeh et al. | Influence of human skin injury on regeneration of sensory neurons | |
| CN111712253A (en) | Neurotoxins to Minimize Scarring | |
| CN110339345B (en) | Recombinant human truncated keratinocyte growth factor-1 eye drops and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |